Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

by David R Clemmons, Sam Miller, Jean-Claude Mamputu
Published 2017-01-01

Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects

by Antonella Napolitano, Sam Miller, Peter R. Murgatroyd, Elizabeth Hussey, Robert L. Dobbins, Edward T. Bullmore, Derek J.R. Nunez
Published 2014-03-01

Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.

by Antonella Napolitano, Sam Miller, Andrew W Nicholls, David Baker, Stephanie Van Horn, Elizabeth Thomas, Deepak Rajpal, Aaron Spivak, James R Brown, Derek J Nunez
Published 2014-01-01

Oscillatory underpinnings of mismatch negativity and their relationship with cognitive function in patients with schizophrenia.

by Muzaffer Kaser, Fruzsina Soltesz, Phil Lawrence, Sam Miller, Chris Dodds, Rodney Croft, Robert B Dudas, Rashid Zaman, Emilio Fernandez-Egea, Ulrich Müller, Anna Dean, Edward T Bullmore, Pradeep J Nathan
Published 2013-01-01

Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections.

by Enrico Domenici, David R Willé, Federica Tozzi, Inga Prokopenko, Sam Miller, Astrid McKeown, Claire Brittain, Dan Rujescu, Ina Giegling, Christoph W Turck, Florian Holsboer, Edward T Bullmore, Lefkos Middleton, Emilio Merlo-Pich, Robert C Alexander, Pierandrea Muglia
Published 2010-02-01

Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.

by Liliana B Menalled, Andrea E Kudwa, Sam Miller, Jon Fitzpatrick, Judy Watson-Johnson, Nicole Keating, Melinda Ruiz, Richard Mushlin, William Alosio, Kristi McConnell, David Connor, Carol Murphy, Steve Oakeshott, Mei Kwan, Jose Beltran, Afshin Ghavami, Dani Brunner, Larry C Park, Sylvie Ramboz, David Howland
Published 2012-01-01

Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.

by Liliana B Menalled, Andrea E Kudwa, Steve Oakeshott, Andrew Farrar, Neil Paterson, Igor Filippov, Sam Miller, Mei Kwan, Michael Olsen, Jose Beltran, Justin Torello, Jon Fitzpatrick, Richard Mushlin, Kimberly Cox, Kristi McConnell, Matthew Mazzella, Dansha He, Georgina F Osborne, Rand Al-Nackkash, Gill P Bates, Pasi Tuunanen, Kimmo Lehtimaki, Dani Brunner, Afshin Ghavami, Sylvie Ramboz, Larry Park, Douglas Macdonald, Ignacio Munoz-Sanjuan, David Howland
Published 2014-01-01